医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IMS Shin-Matsudo Central General Hospital Completes First Patient Treatment with the ZAP-X Gyroscopic Radiosurgery Platform

2024年07月31日 PM11:07
このエントリーをはてなブックマークに追加


 

SHINMATSUDO, Japan

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that IMS Shin-Matsudo Central General Hospital, located in the heart of Shinmatsudo, Chiba, Japan, recently completed its inaugural patient treatment utilizing the cutting-edge ZAP-X® Gyroscopic Radiosurgery® platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731451334/en/

The ZAP-X® Gyroscopic Radiosurgery® Platform. System image courtesy of Hacettepe University Hospital. (Photo: Business Wire)

The ZAP-X® Gyroscopic Radiosurgery® Platform. System image courtesy of Hacettepe University Hospital. (Photo: Business Wire)

Strategically located approximately 25 miles northeast of Tokyo, IMS Shin-Matsudo Central General Hospital stands as a center of medical excellence within the region. As part of the IMS private hospital group, a network of approximately 140 hospitals, clinics, and nursing homes, the newly established Shin Matsudo Accuracy Radiation Therapy (SMART) center is committed to pushing the boundaries of advanced medical care. Leveraging ZAP-X’s groundbreaking vault-free capability, the system now resides on the building’s second floor, and is poised to transform the landscape of radiosurgery treatments.

Stereotactic radiosurgery (SRS) provides a non-invasive option for treating many primary and metastatic brain tumors, as well as other conditions of the head and neck. Notably, SRS has shown equivalent to superior outcomes compared to traditional open surgery. Involving only one to five brief outpatient visits, SRS often allows patients to resume normal activities on the same day as the procedure.

“The introduction of the ZAP-X platform represents a paradigm shift in our approach to radiosurgical care,” said Jun Itami, MD, PhD, Radiation Oncologist, and Director of the SMART Center. “This installation marks the third ZAP-X platform in Japan, and further reaffirms our commitment to pioneering medical advancements.”

Central to its innovation, the ZAP-X system unveils a ground-breaking gyroscopic design capable of guiding radiosurgical beams from thousands of potential unique angles to an exact focal point of high-dose radiation delivery to the targeted tumor. This pioneering approach ideally supports the clinical imperative of minimizing collateral damage to healthy brain tissue and preserving patient cognitive function.

ZAP-X also stands out as the first and only vault-free SRS delivery system, doing away with the necessity for healthcare providers to construct expensive shielded radiation treatment rooms. And by employing a contemporary linear accelerator for radiation generation, ZAP-X is also the first and only dedicated cranial radiosurgery system that no longer relies on Cobalt-60 radioactive sources, thereby eliminating the substantial expenses and efforts associated with hosting, securing, and regularly replacing radioactive isotopes.

About ZAP Surgical Systems, Inc.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler. In addition to being CEO of ZAP, Dr. Adler is Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731451334/en/

CONTACT

Mark Arnold, ZAP Surgical Systems, Inc.

Senior Vice President, Marketing

+1 650 492 7797, ext. 101

Email: info@zapsurgical.com

同じカテゴリーの記事 

  • ニューラプティブ・セラピューティック、NTX-001の第2相トップライン中間結果を2024年米国手外科学会(ASSH)年次総会でプレゼンテーションすると発表
  • オルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®(タピナロフ)クリーム1%を取得
  • Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals
  • Weave Named a Great Place to Work in the U.S. and India
  • Organon将收购Dermavant,包括其创新皮肤疗法VTAMA® (tapinarof) 1%乳膏